Phytother Res: Additional curcub supplementation can improve disease activity in patients with mild and moderate ulcerative colitis

Curcubin has an anti-inflammatory effect, and a randomized double-blind clinical trial recently evaluated its improved effect on ulcerative colitis (UC) disease activity, the results of which were published online in Phytother Res.
study included 70 mild and moderate UC patients randomly assigned to the curculin group (1500mg/day) or placebo group for 8 weeks.
the serum levels of clinical activity, quality of life, tumor necrosis group α (TNF-α), high sensitivity C reactive protein (hs-CRP), red blood cell sedation rate (ESR) and total blood count were measured.
results showed that the change in the index score of simple clinical colitis activity in the curcubin group was significantly higher than that in the placebo group (-5.9 ± 2.08 vs. -2.1 ± 2.6; P s.001).
of inflammatory bowel disease questionnaire-9 and quality of life were significantly higher in the intervention group than in the control group (P - .006).
, curcub supplements reduced serum hs-CRP concentration (-6.3±13.6 vs. compared to the control group. 3.7±11.6 sg/ml; p s .01) and ESR levels (-1.6±2.7 vs. -0.09±2.4 mm/hr; p s .02).
the level of TNF-α in the two groups.
, the results showed that taking curcubin supplements, combined with medication, improved clinical outcomes, quality of life, hs-CRP, and ESR in mild and moderate UC patients.
。